Somaxon Pharmaceuticals and CJ CheilJedang announced today that they have reached an agreement under which CJ CheilJedang will have the exclusive right to commercialize Silenor® (doxepin) in South Korea for the treatment of insomnia.
The terms of the agreement stipulate that Somaxon will collect an up-front payment of US$600,000. CJ CheilJedang will be responsible for regulatory submissions for Silenor and retains the exclusive right to commercialize Silenor in South Korea. Upon Silenor’s approval in South Korea, Somaxon will be eligible to receive sales-based milestone imbursements on top of a net sales based royalty of Silenor in South Korea. Somaxon will be supplying CJ CheilJedang’s requirements for commercial quantities of Silenor at a separate transfer price.
“This transaction helps us further our goal of maximizing the value of Silenor for our stockholders by selectively licensing rights to the product outside of the U.S.,” said Richard W. Pascoe, Somaxon’s President and Chief Executive Officer. “CJ CheilJedang is a leading pharmaceutical company in South Korea with an impressive track record of achieving regulatory approval and effectively commercializing branded pharmaceutical products.”
“We are pleased to partner with Somaxon to commercialize Silenor in South Korea,” said Seok-Hee Kang, Head of Pharmaceutical Business of CJ CheilJedang Corporation. “Silenor is an excellent fit with CJ CheilJedang’s commercial capabilities and portfolio, and we believe that there is a significant unmet need for Silenor.”
For more information, please visit www.silenor.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
